SUMMARY
Nitric oxide (NO) and carbon monoxide (CO) are gasotransmitters that suppress the development of severe forms of malaria associated with Plasmodium infection. Here, we addressed the mechanism underlying their protective effect against experimental cerebral malaria (ECM), a severe form of malaria that develops in Plasmodium-infected mice, which resembles, in many aspects, human cerebral malaria (CM) . NO suppresses the pathogenesis of ECM via a mechanism involving (1) the transcription factor nuclear factor erythroid 2-related factor 2 (NRF-2), (2) induction of heme oxygenase-1 (HO-1), and (3) CO production via heme catabolism by HO-1. The protection afforded by NO is associated with inhibition of CD4 + T helper (T H ) and CD8 + cytotoxic (T C ) T cell activation in response to Plasmodium infection via a mechanism involving HO-1 and CO. The protective effect of NO and CO is not associated with modulation of host pathogen load, suggesting that these gasotransmitters establish a crosstalk-conferring disease tolerance to Plasmodium infection.
INTRODUCTION
Plasmodium infection can lead to the development of cerebral malaria (CM) (Mishra and Newton, 2009) , an often-lethal neurovascular syndrome, triggered by maladaptive host immunity (Miller et al., 2013) and the sequestration of Plasmodiuminfected red blood cells (RBCs) in the brain microvasculature (Taylor et al., 2004) . These pathologic events lead to the disruption of the blood brain barrier (BBB), brain edema, and coma, the hallmarks of CM (Mishra and Newton, 2009) .
As for other clinical manifestations of malaria, CM arises exclusively during the blood stage of Plasmodium infection (Miller et al., 2013) , associated with hemolysis and hence with the generation of cell-free hemoglobin (Hb) (Andrade et al., 2010; Ferreira et al., 2008; Francis et al., 1997) . When oxidized into (ferric) methemoglobin (MetHb), extracellular Hb releases its prosthetic heme groups (Balla et al., 1993; Bunn and Jandl, 1968; Gozzelino et al., 2010) . Free heme is proinflammatory (Figueiredo et al., 2007) , cytotoxic (Balla et al., 1993; Gozzelino et al., 2010; Seixas et al., 2009) , and vasoactive (Belcher et al., 2014) , thus promoting the pathogenesis of experimental cerebral malaria (ECM) (Ferreira et al., 2008 (Ferreira et al., , 2011 Pamplona et al., 2007) , a neurovascular syndrome that develops in Plasmodium berghei ANKA (PbA)-infected mice and that resembles in many aspects human CM that develops in response to P. falciparum infection (Mishra and Newton, 2009) .
The pathogenesis of ECM is fueled by the activation of CD4 + T helper (T H ) and CD8 + cytotoxic T (T C ) cells (Belnoue et al., 2002 (Belnoue et al., , 2008 Nitcheu et al., 2003; Villegas-Mendez et al., 2012 ) that migrate into the brain microvasculature, via a mechanism involving the expression of the chemokines CXCL9, CXCL-10/ IP10, and their cognate receptor CXCR3 (Campanella et al., 2008; Miu et al., 2008 ). Interaction of activated T H and T C with microvascular endothelial cells in the brain compromises BBB integrity via a mechanism involving the expression of Perforin (Prf) (Nitcheu et al., 2003) and granzyme B (GzmB) (Haque et al., 2011) by activated T C cells. This cytotoxic effect synergizes locally with free heme to trigger ECM (Ferreira et al., 2008 (Ferreira et al., , 2011 Gozzelino et al., 2010) .
Mammals have a variety of protective mechanisms restraining the deleterious effects of heme, which converge at the level of heme catabolism by heme oxygenase-1 (HO-1) (encoded by the HMOX1 gene), generating equimolar amounts of carbon monoxide (CO), labile Fe, and biliverdin (Tenhunen et al., 1968) . Induction of HO-1 expression in response to Plasmodium infection suppresses the pathogenesis of ECM (Ferreira et al., 2008 (Ferreira et al., , 2011 Pamplona et al., 2007) as well as the pathogenesis of noncerebral forms of severe malaria in mice (Ferreira et al., 2008; Seixas et al., 2009) . This protective effect is not associated with modulation of host pathogen load, thus suggesting that HO-1 does not regulate host resistance to Plasmodium infection. Instead, HO-1 limits tissue damage imposed to the host during infection, suggesting that it confers disease tolerance (Ayres and Schneider, 2012; Medzhitov et al., 2012; Schneider and Ayres, 2008) to Plasmodium infection. In contrast to resistance to infection, disease tolerance limits disease severity (Schneider, 2011) via a mechanism that does not necessarily impact on the host pathogen load (Medzhitov et al., 2012; Schneider and Ayres, 2008) . In keeping with this notion, the survival advantage afforded by sickle Hb against malaria acts via a mechanism that involves the induction of HO-1, conferring disease tolerance to Plasmodium infection (Ferreira et al., 2011) . Moreover, polymorphisms in the HMOX1 gene correlate with incidence of severe forms of malaria in human populations (Andrade et al., 2010) , including CM (Walther et al., 2012) . Overall, this argues strongly for the involvement of HO-1 in the regulation of disease severity in response to Plasmodium infection in mice as well as in humans.
CO contributes critically to the protective effect of HO-1 against ECM (Ferreira et al., 2008 (Ferreira et al., , 2011 Pamplona et al., 2007) . This salutary effect relies on the avid binding of CO to the prosthetic heme groups of cell-free Hb and the formation of a not readily oxidized carboxyhemoglobin (CO-Hb) complex (Hebbel et al., 1988; Pamplona et al., 2007) . This antioxidant effect restrains the pathogenic effects of cell-free Hb ) and prevents the proinflammatory (Figueiredo et al., 2007) and cytotoxic Larsen et al., 2010; Seixas et al., 2009 ) effects associated with heme release from Hb, from partaking in the pathogenesis of ECM.
Cell-free Hb also contributes to pathogenesis of severe forms of malaria via nitric oxide (NO) scavenging, reducing NO bioavailability (Rother et al., 2005; Gramaglia et al., 2006) and promoting brain microvascular constriction associated with the pathogenesis of ECM (Cabrales et al., 2011; Gramaglia et al., 2006; Ong et al., 2013) . That NO regulates the pathogenesis of severe forms of malaria is supported by the association of several polymorphisms in the genes encoding the nitric oxide synthase (NOS) isoforms 1 (Dhangadamajhi et al., 2009 ), 2 (Hobbs et al., 2002 Trovoada et al., 2014) , and 3 (Dhangadamajhi et al., 2010) with malaria severity in human populations. Moreover, there is also a direct correlation between the levels of NO in plasma and the incidence of severe malaria in human populations (Anstey et al., 1996; Trovoada et al., 2014) . Based on these observations, pharmacologic application of NO has been proposed as a supportive therapy for life-threatening complications of malaria (Hawkes et al., 2011; Yeo et al., 2013) .
Here, we report that the protective effect of NO against ECM acts via a mechanism in which NO induces the expression of HO-1 through activation of the nuclear factor erythroid (NF-E) 2-related factor 2 (Nrf2), a member of the Cap 'n' Collar basic leucine zipper family of transcription factors (Itoh et al., 1999 ) that regulates adaptive cellular responses to oxidative stress Kensler et al., 2007; Suzuki et al., 2013) . CO produced via heme catabolism by HO-1 mediates the protective effects of NO against ECM. NO and CO do not interfere with host pathogen burden, suggesting that these gasotransmitters confer disease tolerance to Plasmodium infection.
RESULTS
NO Confers Disease Tolerance to Plasmodium Infection C57BL/6 mice succumbed to ECM when inoculated with RBCs infected with a transgenic PbA-expressing GFP under the control of the EEF1a promoter; i.e., PbA EEF1a-GFP infection (Figure 1A) . Administration of the NO donor dipropylenetriamine NONOate (DPTA-NO) suppressed the onset of ECM (Cabrales et al., 2011; Gramaglia et al., 2006) , with maximal protection at DPTA-NO administration starting 1-3 days before infection and twice daily thereafter for 7 days ( Figure 1A ). This protective effect was lost when DPTA-NO administration was started 1-3 days after infection ( Figure 1A) . When used at a protective dosage/ schedule, DPTA-NO prevented brain microvascular congestion ( Figure 1B ), BBB disruption ( Figure 1B ), and brain edema ( Figure 1C) ; i.e., the hallmarks of ECM. This protective effect was lost when DPTA-NO was administered 3 days after infection, as assessed for brain edema ( Figure 1C ). DPTA-NO administration did not modulate parasitemia (i.e., percentage of circulating RBCs containing PbA EEF1a-GFP parasites [ Figure 1D ]), while reducing parasite accumulation in the brain versus vehicle-treated controls, as assessed by quantitative real-time RT-PCR ( Figure 1E ). We asked whether NO reduces the sequestration of mature schizonts in the brain, using a transgenic PbA strain expressing a GFP/Luciferase fusion protein in mature schizonts, under the control of the AMA1 promoter; i.e., PbA AMA1-GFP/LUC . NO had no impact on parasitemia, as quantified by the detection of Plasmodium DNA in circulating RBCs (Figure S1A ), morphological detection of parasites in blood smears ( Figure S1B ), or percentage of circulating RBCs containing mature PbA AMA1-GFP/LUC schizonts, as detected by GFP ( Figure S1C ) or by luciferase ( Figures 1F  and 1G ) expression. NO reduced schizont sequestration in the brain, spleen, and heart while increasing sequestration in the lung versus vehicle-treated controls, as quantified by luciferase activity (Figures 1H, S1D-S1G, and S1K). Sequestration was not affected in liver, kidney, and fat ( Figures S1H-S1K ). This suggests that whereas NO does not interfere with parasitemia, it reduces parasite biomass in the brain, an effect that should contribute to suppressing the pathogenesis of ECM (Miller et al., 2013 Figure 1I ). This immunomodulatory effect should also contribute to suppressing the pathogenesis of ECM (Belnoue et al., 2002 (Belnoue et al., , 2008 Nitcheu et al., 2003; Villegas-Mendez et al., 2012) .
The Protective Effect of NO Acts via a Mechanism Involving the Induction of HO-1 Expression DPTA-NO administration induced the expression of Hmox1 mRNA in C57BL/6 mice, as quantified in different organs by quantitative real-time RT-PCR ( Figure 2A ) (Motterlini et al., 1996) . This was associated with induction of HO enzymatic activity, as assessed by the relative rate of biliverdin/bilirubin generation ( Figure 2B ) as well as by CO production; i.e., CO-Hb ( Figure 2C ). When used at a protective dosage/schedule, DPTA-NO failed to protect PbA EEF1a-GFP -infected HO-1-deficient (Hmox1
) mice from succumbing to ECM ( Figures 2D and 2E ). Parasitemias were indistinguishable between Hmox1 +/+ versus Hmox1 À/À mice receiving DPTA-NO or not ( Figure 2F ). This suggests that NO confers disease tolerance to Plasmodium infection via a mechanism that involves the induction of HO-1 expression.
NO Inhibits Neuroinflammation via a Mechanism
Involving HO-1 NO inhibited the accumulation of activated T H and T C cells in the brain of PbA EEF1a-GFP -infected mice, as assessed by quantitative real-time RT-PCR for the expression of several effector molecules involved in the pathogenesis of ECM; i.e., Ctla-4 (Jacobs et al., 2002) , Prf (Nitcheu et al., 2003) , and GzmB (Haque et al., 2011) (Figure 3A) . A similar inhibitory effect was observed for other molecules involved in T H and/or T C activation and presumably therefore driving ECM, including Icos, Cd28, and Fas ligand (Fasl) ( Figure 3A ), among others ( Figure S2 ). This immunomodulatory effect was lost in Hmox1 À/À mice ( Figures 3A and S2 ).
NO inhibited the expression of mRNA-encoding Cd45 in the brain of infected Hmox1 +/+ mice, but not in Hmox1
mice, confirming that NO prevents overall leukocyte accumulation in the brain ( Figure 3B mice receiving DPTA-NO (50 mg/kg, twice daily, 12 hr apart) at different schedules relative to the day of infection (day 0); i.e., from À3 to +7 (n = 9), À1 to +7 (n = 13), +1 to +10 (n = 6), and +3 to +7 (n = 7). Control mice received vehicle (PBS; n = 28).
Six independent experiments with similar trend were performed. mice receiving vehicle (PBS; n = 7) versus DPTA-NO (n = 7). Two independent experiments analyzed at day 7 after infection were performed. *p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05. See also Figure S1 .
pathogenesis of ECM ( Figure S2 ). This suggests that NO inhibits neuroinflammation associated with Plasmodium infection via a mechanism involving HO-1. reduced the total number of lymphocytes and T C cells in the spleen of infected mice, as compared to infected air-treated controls ( Figure S3B ). Given that (1) NO induces HO-1 (Figures 2A and 2B ) and CO production ( Figure 2C ) and (2) CO mimics the immunoregulatory effect of NO during Plasmodium infection, we infer that this effect of NO is probably mediated via a mechanism involving CO. These data, however, do not prove that CO is necessary to support the immunoregulatory effect of NO.
NO and CO Restrain T H and T C Cell Activation in Response to

The Protective Effect of NO Acts via a Mechanism Involving Nrf2
NO induces HO-1 expression in vitro (Motterlini et al., 1996) via a mechanism involving the transcription factor Nrf2 (Naughton et al., 2002) . We asked whether a similar mechanism occurs in vivo to prevent the pathogenesis of ECM. Nrf2 deletion in C57BL/6 mice impaired the induction of Hmox1 mRNA in response to DPTA-NO, as assessed in different organs by quantitative realtime RT-PCR ( Figure 5A ). This correlated with lack of HO activity ( Figure 5B ), demonstrating that NO induces HO-1 and raises HO activity in vivo, via an Nrf2-dependent mechanism.
When administered at a protective dosage/schedule, NO failed to protect Nrf2 À/À mice from succumbing to ECM ( Figure 5C ).
Parasitemias were similar in Nrf2 À/À versus Nrf2 +/+ mice receiving DPTA-NO or not ( Figure 5D ). Mortality of infected Nrf2
mice receiving DPTA-NO was associated with brain edema (Figure 5E) . This suggests that Nrf2 activation by NO suppresses ECM and confers disease tolerance to Plasmodium infection. CO administration restored the protective effect of DPTA-NO in PbA
EEF1a-GFP -infected Nrf2 À/À mice ( Figure 5F ), without interfering with parasitemia ( Figure 5G ). This suggests that the protective effect of NO against ECM is mediated via a mechanism that involves CO. These data, however, do not prove that CO is necessary to support the protective effect of Nrf2.
HO-1 Does Not Regulate NO Bioavailability during
Plasmodium Infection DPTA-NO administration increased the concentration of the two major end products of NO oxidation (i.e., nitrite and nitrate, in the plasma of noninfected or PbA EEF1a-GFP -infected mice) in comparison to vehicle-treated controls ( Figure 6A ). DPTA-NO administration was also associated with the accumulation, in the brain of PbA EEF1a-GFP -infected mice, of the end product of the NO-regulated enzyme guanylate cyclase cyclic guanosine monophosphate (cGMP) ( Figure 6B ) (Gramaglia et al., 2006) . Concentration of nitrite/nitrate in the plasma of PbA EEF1a-GFP -infected Hmox1 À/À or Nrf2 À/À mice was similar to that of wild-type (WT) controls ( Figure 6A ). The same was true for cGMP accumulation in the brain ( Figure 6B ). This suggests that expression of Nrf2-regulated genes, including HO-1, does not modulate NO bioavailability during Plasmodium infection. Moreover, this excludes that failure of NO to suppress the pathogenesis of ECM in Hmox1 À/À or Nrf2 À/À mice is due to a putative reduction of NO availability.
Nrf2 and HO-1 Limit the Pro-oxidant Effect of NO Exerted on Cell-free Hb
Although NO and CO target cell-free Hb, they should act in opposite ways, with NO propagating Hb oxidation and CO preventing it (Hebbel et al., 1988; Pamplona et al., 2007) . NO increased the concentration of MetHb in the plasma of noninfected as well as in PbA EEF1a-GFP -infected WT mice, as compared to vehicle-treated controls ( Figure 6C ). This effect was exacerbated in infected Hmox1 À/À or Nrf2 À/À mice versus WT controls ( Figure 6C ). This suggests that regulation of HO-1 expression by Nrf2 restrains the oxidation of cell-free Hb by NO, during Plasmodium infection. PbA EEF1a-GFP infection was associated with the accumulation of non-Hb-bound heme (i.e., free heme), in the plasma of WT mice ( Figure 6D ). This effect was exacerbated in Hmox1 See also Figure S2 .
Plasmodium infection, an effect that should contribute to the protective effect of NO against ECM (Ferreira et al., 2008) .
The Protective Effect of CO against ECM Acts Independently of NO We assessed whether the protective effect of CO against ECM acts via a mechanism involving endogenous NO production by different NOS. CO administration via inhalation protected PbA EEF1a-GFP -infected mice carrying combined deletions of
, and Nos1/Nos3 À/À [ Figure 7C ]) from succumbing to ECM. Similar effects were observed in Nos1 À/À ( Figure S4A ),
Nos2
À/À ( Figure S4B ), and Nos3 À/À ( Figure S4C ) mice. The protective effect of CO was associated with inhibition of brain edema ( Figures 7D and S4D ), suggesting that CO is sufficient and likely acts downstream of NO to suppress the pathogenesis of ECM. This observation also suggests that the protective effect of CO does not require endogenous NO production, although this has not been established conclusively. Time of ECM onset was delayed in mice carrying a deletion of the neuronal Nos1 allele (i.e., Nos1 À/À ( Figure S4A ), Nos1/ Nos2 À/À [ Figure 7A ], and Nos1/Nos3 À/À [ Figure 7C] S4C , and 7B).
DISCUSSION
When used pharmacologically, NO (Cabrales et al., 2011; Gramaglia et al., 2006; Ong et al., 2013) and CO (Ferreira et al., 2008 (Ferreira et al., , 2011 Pamplona et al., 2007) suppress the pathogenesis of ECM. The mechanism(s) underlying this salutary effect and the potential use of these gasotransmitters as adjunctive therapies to treat severe forms of malaria in humans remain to be established (Hawkes et al., 2011) . The term gasotransmitter as used hereby refers to biologic active gaseous molecules produced physiologically (Mustafa et al., 2009) . NO is generated by the enzymatic conversion of L-arginine and molecular oxygen to L-citrulline, catalyzed by different NOS isoforms, whereas CO is generated through the enzymatic conversion of heme and molecular oxygen, catalyzed by different HO isoforms (Tenhunen et al., 1968) . In contrast to CO, NO is a labile-free radical with potentially deleterious prooxidant activity ( Figure 6C ) ) that can act locally in the brain to promote the pathogenesis of CM. Consistent with this notion, stable end products of NO accumulate in the cerebral spinal fluid of individuals with adverse disease outcome from CM (Weiss et al., 1998) . Moreover, deletion of the neuronal NOS isoform (i.e., Nos1, confers some level of protection against ECM [ Figures 7 and S4] ), suggesting that when produced locally in the brain, NO is deleterious and promotes, rather than protects from, ECM.
When applied pharmacologically to mice, NO acts systemically to suppress the pathogenesis of ECM (Figure 1) (Cabrales et al., 2011; Gramaglia et al., 2006; Ong et al., 2013) . This suggests that whereas NO can act systemically to confer protection against malaria, its bioavailability during Plasmodium infection is not sufficient to afford this salutary effect. This is attributed most likely to NO scavenging by cell-free Hb Gramaglia et al., 2006) as well as to reduction of NOS2 expression (Weiss et al., 1994) , presumably driven by cellular iron overload (Gozzelino et al., 2012; Gozzelino and Soares, 2014) . Reduced NO bioavailability promotes brain microvascular constriction, thus fostering the pathogenesis of ECM (Cabrales et al., 2011; Gramaglia et al., 2006; Ong et al., 2013) . NO administration compensates for reduced systemic NO bioavailability during Plasmodium infection, preventing the pathogenesis of ECM. Although we confirmed that NO administration suppresses the pathogenesis of ECM (Figure 1) (Cabrales et al., 2011; Gramaglia et al., 2006; Ong et al., 2013) , we found that this protective effect relies on the induction of HO-1 (Figure 2) , via a mechanism involving the transcription factor Nrf2 ( Figure 5 ). Induction of HO-1 leads to the production of CO (Figure 2) (Motterlini et al., 1996) , a gasotransmitter that suppresses the pathogenesis of ECM (Figures 5, 7 , and S4). NO acts most likely as a ''doubleedged'' sword during Plasmodium infection, promoting Hb oxidation ( Figure 6C ) as well as the expression of HO-1 and the production of CO (Figure 2 ), limiting Hb oxidation ( Figure 6D ). Presumably, HO-1 and CO contribute to the protective effect of NO (Figures 2 and 5 ) by suppressing Hb oxidation and heme release from Hb, thus preventing heme from partaking in the pathogenesis of ECM (Ferreira et al., 2008 (Ferreira et al., , 2011 Pamplona et al., 2007) . These effects of HO-1 and CO, which limit the pro-oxidant effect of NO, probably allow this gasotransmitter to exert additional salutary effects that act irrespectively of HO-1 and CO.
NO has no apparent impact on pathogen load, suggesting that this gasotransmitter confers disease tolerance to the blood stage of Plasmodium infection (Figure 1) . However, NO reduces parasite sequestration in the brain ( Figures 1H and S1D ), a salutary effect that should contribute to suppressing the onset of ECM as well as that of CM (Miller et al., 2013) . NO also inhibits the activation, proliferation, and expansion of pathogenic T H and T C in the spleen during the blood stage of Plasmodium infection (Figure 4) . This prevents the accumulation of T H and T C cells in the brain of infected mice (Figure 1 ), reducing neuroinflammation ( Figure 3) and, as such, suppressing the pathogenesis of ECM (Miller et al., 2013) . This salutary effect is probably exerted via the pro-oxidant activity of NO, which suppresses T cell responses (Hoffman et al., 1990 ) through the induction of T cell apoptosis (Brito et al., 1999) . NO may also act indirectly, via the induction of HO-1, to induce T cell apoptosis (McDaid et al., 2005; Soares et al., 2009 ).
When applied to Nos1-deficient mice (i.e., Nos1
), CO exerts a negative impact on parasitemia ( Figures S4A, 7A, and 7C ). This effect is only observed in Nos1-deficient mice, presumably because a small fraction of these mice escapes ECM ( Figures S4A, 7A , and 7C), thus allowing for comparison of parasitemia over time. This suggests that CO modulates not only disease tolerance, early during Plasmodium infection (i.e., preventing CM without impacting on pathogen load) but also resistance (i.e., reducing pathogen load) later on, in comparison to control mice that do receive CO. This latter effect of CO may be exerted via a direct interaction of this gasotransmitter with the pathogen or indirectly via modulation of host-resistance mechanisms ).
In conclusion, the salutary effect exerted by NO during Plasmodium infection is mediated to at least some extent, indirectly, ) mice receiving vehicle or DPTA-NO (NO; 50 mg/kg twice 12 hr apart; n = 5 per group), as assessed by qRT-PCR. Samples were collected 4 hr after the last DPTA-NO administration. The y axis scale is the same as in Figure 2A , for comparison. (B) HO activity is shown as mean pmol bilirubin/mg of tissue/hr ± SD in mice treated as in (A) (n = 4 mice per group). The y axis scale is the same as in Figure 2B by CO. This interplay between the two gasotransmitters should be taken into consideration when envisioning their therapeutic application as adjunctive therapies against severe forms of malaria.
EXPERIMENTAL PROCEDURES Mice
Mice were bred and maintained under specific pathogen-free (SPF) conditions. Protocols were approved by the Ethics Committee of the Instituto Parasitemias were determined by flow cytometry (Ferreira et al., 2011) and/or by Giemsa-stained blood smears. Mice were monitored daily for clinical signs of ECM, including hemi-or paraplegia, head deviation, tendency to rollover on stimulation, ataxia, and convulsions. The day of infection is zero (0) in all experiments.
NO Treatment
Mice received DPTA-NO (Alexis Biochemicals) i.p. (50 mg/kg of body weight dissolved in 200 ml of PBS) twice daily with different schedules as indicated in the figures. DPTA-NO was prepared freshly in ice-cold PBS and injected immediately thereafter.
CO Treatment
Mice were placed in a gastight 60-liter capacity chamber and exposed continuously between days 3 and 6 postinfection to CO at a flow rate of $12 l/min (final concentration of 250 ppm) (Sato et al., 2001) . CO concentration was monitored continuously using a CO analyzer (Interscan).
Luciferase Imaging
Mice were infected with PbA AMA1-GFP/LUC , treated with vehicle or DPTA-NO (day À1 to +7), and luciferase activity was determined at the time of ECM onset in control mice (i.e., day 7). Luciferase activity was visualized by whole-mice imaging or in dissected tissues using an electron-multiplying charge-coupled device (EM-CCD) photon-counting camera (ImagEM; Hamamatsu).
Brain Edema
Brain edema was evaluated using Evans blue, administered intravenously (2% solution, 100 ml; Sigma-Aldrich), as described by Pamplona et al. (2007) .
HO-1 Activity
Mice were injected (i.p.) with DPTA-NO or vehicle twice 12 hr apart, and HO activity was measured 4 hr thereafter in tissues snap-frozen in liquid nitrogen, as described by Sato et al. (2001) .
Endogenous CO Production
Mice were treated with vehicle or DPTA-NO as detailed for HO-1 activity determination. Blood was collected from the facial vein (200 ml) into a heparinized tube (10 ml), transferred to an assay cuvette, and analyzed using an Avoximeter 4000 (ITC) for total Hb (g/dl) and CO-Hb (percentage of total Hb) content.
Histology
Brains were harvested when clinical signs of ECM were observed in control mice. Tissue was fixed in buffered 4% (v/v) paraformaldehyde and embedded in paraffin. Paraffin sections were cut at 12 mm, stained with hematoxylin and eosin (H&E), and analyzed via an Olympus BX51 light microscope.
Quantitative Real-Time PCR Mice were sacrificed at the day of ECM onset in control mice. Total RNA was isolated from the different organs using TRIzol (Invitrogen Life Technologies) and the RNeasy Mini Kit (QIAGEN) and used to synthesize cDNA for PCR with Power SYBR Green PCR master mix (Invitrogen Life Technologies). Transcript number was calculated from the threshold cycle (Ct) of each gene with a 2
ÀDDCT method (relative number) and normalized to hypoxanthine-guanine phosphoribosyltransferase (Hprt) or glucuronidase b (Gusb).
Mouse Immune Quantitative RT-PCR Array
TaqMan gene signature mouse immune array (Applied Biosystems) was used to quantify all other mRNAs according to manufacturer's recommendations (Ferreira et al., 2011) . Gene expression was determined as above.
T Cell Activation
Analyses of T cell activation were performed in the spleens of naive or PbA EEF1a-GFP -infected C57BL/6 mice at 5.5 days postinfection, as described in Ferreira et al. (2011) . 
, or Nrf2
À/À mice receiving DPTA-NO (n = 13 for WT, n = 7 for Hmox1 À/À mice and n = 12 for Nrf2 À/À mice) or vehicle (n = 14 for WT, n = 9 for Hmox1 À/À mice and n = 12 for Nrf2 À/À mice). Three independent experiments were performed.
NO donor DPTA-NO was administered from day À1 to day 6 postinfection. (C) Mean concentration of MetHb ± SD in the plasma of noninfected or PbA EEF1a-GFP -infected mice receiving vehicle (PBS) or DPTA-NO (NO; 50 mg/kg twice daily, 12 hr apart from day À1 to +6). Measurements were taken on day 6 postinfection. Three experiments (n = 5-12 mice per group) with similar trend were performed. (D) Mean concentration of non-Hb-bound (free) heme ± SD in the plasma of the same mice as in (C). *p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05.
Cell Reports 8, 126-136, July 10, 2014 ª2014 The Authors 133
Statistics Survival curves were represented as Kaplan-Meier plots, and significance was evaluated with the log rank (Mantel-Cox) test. Comparison of the means of three or more groups was performed using one-way ANOVA, and significance between every two groups was assessed by the Bonferroni multiple comparison test when data assumed Gaussian distribution, as assessed by the D'Agostino and Pearson omnibus normality test. For samples with a ''(n)'' not allowing to ascertain Gaussian distribution, group comparison was analyzed using the Kruskal-Wallis test, followed by Mann-Whitney U test for assessment of significance between every two groups. Outliers were identified with the Grubbs' test from the GraphPad software, available online (http:// graphpad.com/quickcalcs/Grubbs1.cfm). All tests were performed with the GraphPad v.5.0a software (Prism), and p values were represented as *p < 0.05, **p < 0.01, and ***p < 0.001. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Mice: C57BL/6 Nrf2 -/-mice were provided originally from the RIKEN BioResource Center (Koyadai, Tsukuba, Ibaraki, Japan) and maintained at the Instituto Gulbenkian de Ciência. C57BL/6 Nos1 -/- (Huang et al., 1993) , Nos2 -/- (Laubach et al., 1995) , Nos3 -/- (Shesely et al., 1996) Infection assessment: For PbA AMA1-GFP/LUC infections parasitemias were determined by morphological assessment of infected RBCs in Giemsa-stained blood smears.
Percentage of GFP + RBCs in PbA AMA1-GFP/LUC and PbA EEF1a-GFP was determined by flow cytometry, as described (Ferreira et al., 2011) . DNA + RBCs were determined in the same flow cytometry analysis by incorporation of Draq5 TM (Biosatus). Flow cytometry was performed in a FacScan analyzer (BD biosciences) and data was analyzed with FlowJo software (Tree Star Inc.).
Luciferase activity quantification:
Mice were anesthetized with ketamine, ventral area was shaved and imaged 5min after administration of d-Luciferin (i.p. in PBS; 25mg/kg; Promega). Mice received a second injection of luciferin (i.p. in PBS; 25mg/kg) and were sacrificed 5min thereafter, perfused in toto with PBS and organs were harvested and placed on glass slides for imaging. Non-infected mice were used for background subtraction. To minimize differences in measurement due to signal decay, each set of mice or organs, was imaged at equivalent times after administration of luciferin. Images were acquired in 16 bit mode, with an EM-CCD, ImagEM Hamamatsu camera, coupled to a Schneider Kreuznach Xenon 25mm 1:0.95/25 lens and using the Hammatsu HCI software, with "sensitivity gain1" adjusted to 160.00 and "Gain" adjusted to 5.00 for all images. Multiple images were acquired for each sample with exposure times ranging form 10 to 120s to maximize signal and avoid saturation. For each sample, an image of the sample illuminated with bright-white light was also acquired. Pseudocolor images were superimposed on grayscale reference images and analyzed using the FIJI (ImageJ 1.48o) software (Schindelin et al., 2012) . Images obtained with equal exposure times with no saturated pixels (whole mouse: 30s; brain: 120s; heart and kidney: 60s; liver, spleen and lung: 30s; fat: 10s) were compared. Luminescence channel was represented using a pseudocolor scale for intensity comparison. Overlays of the pseudocolor luminescence and grayscale reference images were used to draw Regions of Interest (ROI). For whole animal images, ROI was restricted to shaved areas. The intensity of the luciferase signal was assessed for each ROI as average pixel gray levels, referred to as "Relative Light Units" (RLU), and expressed as RLU per cm 2 per second.
Heme determinations: Blood was collected in heparinized tubes by cardiac puncture and centrifuged (2x5min, 1600g). Plasma Hb and MetHb concentrations were determined by spectroscopy at λ=577nm and λ=630nm as described (Winterbourn, 1985) . Total plasma heme content was measured using the 3,3'; 5,5' tetramethylbenzidine (TMB) peroxidase assay (OptEIA TMB Substrate Reagent Set BD Biosciences). Briefly, 1µL of plasma was mixed with 200µL of TMB reagent. After 30min of incubation in dark absorbance was determined at λ=655 nm. Purified Hb was used as standard for plasma Hb and heme measurements. Concentration of free heme was calculated by subtracting Hb-heme and MetHb-heme from total heme.
HO-1 activity:
Tissue samples were used to determine Bilirubin production and was Samples were sonicated again, centrifuged and the supernatant was used to determine HO activity using rat liver cytosol as a source of biliverdin reductase (2mg/assay), hemin (20mM), glucose 6-phosphate (2mM), glucose 6-phosphate dehydrogenase (0.2U/reaction) and NADPH (0.8mM)(400μL, 3 0 C, 1h). Bilirubin was extracted (1mL of chloroform; vortexing 3x10s). After centrifugation optical densities of the organic phase were determined at λ=464 nm and λ=530 nm.
